AstraZeneca Targets $80 Billion Revenue by 2030 with 20 New Medicines

May 21, 2024, 07:19 AM

AstraZeneca has set an ambitious target to nearly double its revenue to $80 billion by 2030. This goal is driven by the planned launch of 20 new medicines and growth in its existing oncology, biopharmaceuticals, and rare disease portfolio. CEO Pascal Soriot aims to cement his legacy at the British drugmaker with this significant revenue target. The new target surpasses analyst forecasts and reflects AstraZeneca's confidence in its pipeline expansion and sustained growth post-2030. The company also expects double-digit growth in its oncology division.